Hyperuricemia—a serious complication among patients with chronic kidney disease: a systematic review and meta-analysis

Abstract

Aim: Hyperuricemia as a putative risk factor for chronic kidney disease (CKD) progression remains controversial and debatable. This systematic review aims to explore the prevalence of hyperuricemia among CKD patients worldwide. Methods: This study was conducted in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines by using the existing literature from online databases such as MEDLINE/PubMed, ScienceDirect, Google Scholar, Cochrane library and grey literature. The effect size with corresponding 95% confidence interval (CI) was calculated to assess the pooled prevalence of hyperuricemia in chronic kidney patients. The subgroup analysis based on gender and geography was also carried out by utilizing comprehensive meta-analysis, version 2.0. Results: Twenty-three studies containing 212,740 participants were eligible for quantitative synthesis. The pooled prevalence of 43.6% (35.2–52.4%) hyperuricemia was reported in patients with CKD globally. In India, 38.4% of prevalence was observed. The gender specific prevalence (9 studies) was reported as 67.4% (60.9–73.3%) in case of male patients and 32.6% (26.7–39.1%) in female patients with 95% CI. Conclusions: The prevalence of hyperuricemia was reported to be reasonably high among CKD patients worldwide. During the management of CKD, this high prevalence demands more prudent attention for this clinical complication which possibly can lead to positive renal outcomes.

Calycosin attenuates renal ischemia/reperfusion injury by suppressing NF-κB mediated inflammation via PPARγ/EGR1 pathway

“…Acute kidney injury (AKI) is defined as a rapid decrease in kidney function with increased serum creatinine levels and/or decreased urine output. AKI occurs in approximately 10%-15% of hospitalized patients, which is increasingly recognized as a risk factor for chronic kidney disease (CKD) (Ronco et al, 2019;Rashid et al, 2022). However, there is no effective prevention and treatment for AKI (Zhou et al, 2020;Li et al, 2021).…”

Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy

“…Genomics, transcriptomics, proteomics, and metabolomics are related to genome (DNA), transcriptome (RNA), proteome (proteins) and metabolome (metabolites), respectively ( Zhao and Lin., 2014 ). High morbidity and mortality of chronic kidney disease (CKD) has emerged as a major public health problem worldwide ( Mantovani and Chiara., 2020 ; Malaki, 2022 ; Rashid et al, 2022 ). Multi-omics techniques have been extensive applied to the biomarker discovery, diagnosis and prognosis, drug pharmacological and toxicity evaluation in a variety of diseases including ( Cisek et al, 2016 ; Yang, 2020 ; Joshi et al, 2021 ).…”

Metabolomic profiles in serum and urine uncover novel biomarkers in children with nephrotic syndrome

“…It is estimated that the global prevalence of CKD is approximately 13.4% (11.7–15.1%), presumably affecting 107.2 billion patients and causing a financial burden for public health insurance 5,6 . CKD had rapid and inevitable disease progression and predisposing factors for many other diseases, including end‐stage renal disease and cardiovascular disease 7 . Therefore, early detection the kidney injury, especially in early life in childhood, is an effective way to decrease disease incidence.…”